Effects of repeat prenatal corticosteroids given to women at risk of preterm birth:an individual participant data meta-analysis by 
 
 
University of Birmingham
Effects of repeat prenatal corticosteroids given to
women at risk of preterm birth
PRECISE Group
DOI:
10.1371/journal.pmed.1002771
License:
Creative Commons: Attribution (CC BY)
Document Version
Publisher's PDF, also known as Version of record
Citation for published version (Harvard):
PRECISE Group 2019, 'Effects of repeat prenatal corticosteroids given to women at risk of preterm birth: an
individual participant data meta-analysis', PLoS Medicine, vol. 16, no. 4, e1002771.
https://doi.org/10.1371/journal.pmed.1002771
Link to publication on Research at Birmingham portal
Publisher Rights Statement:
Checked for eligibility: 18/07/2019
General rights
Unless a licence is specified above, all rights (including copyright and moral rights) in this document are retained by the authors and/or the
copyright holders. The express permission of the copyright holder must be obtained for any use of this material other than for purposes
permitted by law.
•	Users may freely distribute the URL that is used to identify this publication.
•	Users may download and/or print one copy of the publication from the University of Birmingham research portal for the purpose of private
study or non-commercial research.
•	User may use extracts from the document in line with the concept of ‘fair dealing’ under the Copyright, Designs and Patents Act 1988 (?)
•	Users may not further distribute the material nor use it for the purposes of commercial gain.
Where a licence is displayed above, please note the terms and conditions of the licence govern your use of this document.
When citing, please reference the published version.
Take down policy
While the University of Birmingham exercises care and attention in making items available there are rare occasions when an item has been
uploaded in error or has been deemed to be commercially or otherwise sensitive.
If you believe that this is the case for this document, please contact UBIRA@lists.bham.ac.uk providing details and we will remove access to
the work immediately and investigate.
Download date: 01. Mar. 2020
RESEARCH ARTICLE
Effects of repeat prenatal corticosteroids
given to women at risk of preterm birth: An
individual participant data meta-analysis
Caroline A. CrowtherID1,2*, Philippa F. MiddletonID2,3, Merryn VoyseyID4, Lisa Askie5,
Sasha Zhang2, Tanya K. Martlow2, Fariba AghajafariID6, Elizabeth V. AsztalosID7,
Peter Brocklehurst8, Sourabh DuttaID9, Thomas J. Garite10, Debra A. Guinn11,
Mikko HallmanID12, Pollyanna HardyID8, Men-Jean LeeID13, Kimberley MaurelID10,
Premasish MazumderID9, Cindy McEvoyID14, Kellie E. MurphyID7, Outi M. Peltoniemi12,
Elizabeth A. ThomID15, Ronald J. Wapner16, Lex W. Doyle17,18,19, the PRECISE Group¶
1 Liggins Institute, University of Auckland, Auckland, New Zealand, 2 Robinson Research Institute,
Discipline of Obstetrics and Gynaecology, School of Medicine, The University of Adelaide, Adelaide,
Australia, 3 Healthy Mothers Babies and Children, South Australian Health and Medical Research Institute,
Adelaide, Australia, 4 Nuffield Department of Primary Care Health Sciences and Department of Paediatrics,
University of Oxford, Oxford, United Kingdom, 5 NHMRC Clinical Trials Centre, University of Sydney,
Sydney, Australia, 6 Department of Family Medicine, Cumming School of Medicine, University of Calgary,
Calgary, Alberta, Canada, 7 Department of Paediatrics and Obstetrics/Gynecology, University of Toronto,
Toronto, Ontario, Canada, 8 Birmingham Clinical Trials Unit, Institute of Applied Health Research, University
of Birmingham, Birmingham, United Kingdom, 9 Division of Neonatology, Department of Pediatrics,
Postgraduate Institute of Medical Education and Research, Chandigarh, India, 10 Mednax Inc., Sunrise,
Florida, United States of America, 11 Kalispell Regional Health Care, Kalispell, Montana, United States of
America, 12 Department of Paediatrics, University of Oulu, Oulu, Finland, 13 John A Burns School of
Medicine, University of Hawaii, Honolulu, Hawaii, United States of America, 14 Department of Pediatrics,
Oregon Health and Science University, Portland, Oregon, United States of America, 15 The Biostatistics
Center, George Washington University, Washington, DC, United States of America, 16 Department of
Obstetrics and Gynecology, Division of Maternal Fetal Medicine, Columbia University Medical Center, New
York, New York, United States of America, 17 Department of Obstetrics and Gynaecology, The Royal
Women’s Hospital, University of Melbourne, Melbourne, Australia, 18 Clinical Sciences, Murdoch Children’s
Research Institute, Parkville, Victoria, Australia, 19 Department of Paediatrics, University of Melbourne,
Parkville, Victoria, Australia
¶ Membership of the PRECISE Group is provided in the Acknowledgements.
* c.crowther@auckland.ac.nz
Abstract
Background
Infants born preterm compared with infants born at term are at an increased risk of dying
and of serious morbidities in early life, and those who survive have higher rates of neurologi-
cal impairments. It remains unclear whether exposure to repeat courses of prenatal cortico-
steroids can reduce these risks. This individual participant data (IPD) meta-analysis (MA)
assessed whether repeat prenatal corticosteroid treatment given to women at ongoing risk
of preterm birth in order to benefit their infants is modified by participant or treatment factors.
Methods and findings
Trials were eligible for inclusion if they randomised women considered at risk of preterm
birth who had already received an initial, single course of prenatal corticosteroid seven or
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more days previously and in which corticosteroids were compared with either placebo
or no placebo. The primary outcomes for the infants were serious outcome, use of respira-
tory support, and birth weight z-scores; for the children, they were death or any neurosen-
sory disability; and for the women, maternal sepsis. Studies were identified using the
Cochrane Pregnancy and Childbirth search strategy. Date of last search was 20 January
2015. IPD were sought from investigators with eligible trials. Risk of bias was assessed
using criteria from the Cochrane Collaboration. IPD were analysed using a one-stage
approach.
Eleven trials, conducted between 2002 and 2010, were identified as eligible, with five tri-
als being from the United States, two from Canada, and one each from Australia and New
Zealand, Finland, India, and the United Kingdom. All 11 trials were included, with 4,857
women and 5,915 infants contributing data. The mean gestational age at trial entry for
the trials was between 27.4 weeks and 30.2 weeks. There was no significant difference in
the proportion of infants with a serious outcome (relative risk [RR] 0.92, 95% confidence
interval [CI] 0.82 to 1.04, 5,893 infants, 11 trials, p = 0.33 for heterogeneity). There was a
reduction in the use of respiratory support in infants exposed to repeat prenatal corticoste-
roids compared with infants not exposed (RR 0.91, 95% CI 0.85 to 0.97, 5,791 infants, 10
trials, p = 0.64 for heterogeneity). The number needed to treat (NNT) to benefit was 21
(95% CI 14 to 41) women/fetus to prevent one infant from needing respiratory support.
Birth weight z-scores were lower in the repeat corticosteroid group (mean difference −0.12,
95%CI −0.18 to −0.06, 5,902 infants, 11 trials, p = 0.80 for heterogeneity). No statistically
significant differences were seen for any of the primary outcomes for the child (death or
any neurosensory disability) or for the woman (maternal sepsis). The treatment effect var-
ied little by reason the woman was considered to be at risk of preterm birth, the number of
fetuses in utero, the gestational age when first trial treatment course was given, or the
time prior to birth that the last dose was given. Infants exposed to between 2–5 courses
of repeat corticosteroids showed a reduction in both serious outcome and the use of respi-
ratory support compared with infants exposed to only a single repeat course. However,
increasing numbers of repeat courses of corticosteroids were associated with larger
reductions in birth z-scores for weight, length, and head circumference. Not all trials could
provide data for all of the prespecified subgroups, so this limited the power to detect differ-
ences because event rates are low for some important maternal, infant, and childhood
outcomes.
Conclusions
In this study, we found that repeat prenatal corticosteroids given to women at ongoing risk
of preterm birth after an initial course reduced the likelihood of their infant needing respira-
tory support after birth and led to neonatal benefits. Body size measures at birth were
lower in infants exposed to repeat prenatal corticosteroids. Our findings suggest that to
provide clinical benefit with the least effect on growth, the number of repeat treatment
courses should be limited to a maximum of three and the total dose to between 24 mg and
48 mg.
Repeat prenatal corticosteroids prior to preterm birth
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Author summary
Why was this study done?
• Effective therapies that can reduce the risk of infants born preterm having respiratory
and other health problems early in life and prevent later neurological impairments are
needed. A single course of prenatal corticosteroids prior to expected or planned preterm
birth remains the gold standard treatment to reduce these risks.
• If birth does not occur, it has been unclear whether giving women who remain at high
risk of preterm birth a repeat course or courses of prenatal corticosteroids can similarly
reduce the risks for the infant.
• The aims of the Prenatal Repeat Corticosteroid International IPD-MA Study: assessing
the effects using the best level of Evidence (PRECISE) individual participant data meta-
analysis (IPD-MA) were to assess the effect of repeat prenatal corticosteroids when
given to women at high, ongoing risk of preterm birth on important clinical outcomes
and whether treatment effects varied depending on participant and treatment factors.
What did the researchers do and find?
• Eleven randomised trials with 4,857 women and 5,915 infants were identified as includ-
ing women at ongoing risk of preterm birth after an initial course of prenatal corticoste-
roids who were allocated repeat prenatal corticosteroids or placebo or no placebo
treatment and in which outcomes for the infant were reported and included.
• Overall, repeat prenatal corticosteroids given to women at ongoing risk of preterm birth
after an initial course did not reduce the risk of serious health outcomes for the infant
but did reduce the need for respiratory support, although birth weight z-scores were
reduced. Exposure to more repeat courses and greater total dose of corticosteroids was
associated with a reduction in serious outcome and less need for respiratory support for
the infant but also greater reduction in body size at birth. There were no differences in
rates of maternal sepsis. At childhood follow-up, no differences in neurodevelopment
were seen between those exposed to repeat prenatal corticosteroids and those not,
although weight z-scores and systolic blood pressure measurements were lower in the
exposed group.
• Treatment effects varied little by reason for preterm birth, the number of fetuses in
utero, the gestational age when repeat treatment was given, or the time prior to birth
that the last dose was given.
What do these findings mean?
• Repeat prenatal corticosteroids given to women at ongoing risk of preterm birth after
an initial course reduce the likelihood of their infant needing respiratory support after
birth and lead to other respiratory benefits.
Repeat prenatal corticosteroids prior to preterm birth
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• To provide clinical benefit with the least effect on growth, the number of repeat treat-
ment courses should be limited if possible. We suggest a maximum of three repeat treat-
ments and a total dose of between 24 mg and 48 mg.
• Reductions in weight z-scores and systolic blood pressure seen at childhood follow-up
are of uncertain clinical importance and warrant further study.
• Adoption of repeat prenatal corticosteroid treatment used in this way could lead to both
significant health benefits for infants at ongoing risk of preterm birth after exposure to
an initial course of corticosteroids while minimising any reduction in body size.
Introduction
Respiratory distress syndrome, caused by surfactant deficiency, is a common complication of
preterm birth and a major cause of early neonatal mortality and morbidity [1]. Infants born
preterm often require respiratory support, with significant numbers requiring assisted ventila-
tion and treatment with exogenous surfactant [1]. Children born preterm who survive have a
higher risk of subsequent long-term neurodevelopmental impairments such as cerebral palsy,
cognitive dysfunction, blindness, and deafness than do children born at term [2,3]. The global
burden is substantial, with estimates suggesting up to 8% of preterm infants have neurological
impairments [4]. The personal and emotional costs for affected individuals and their families
are high, as are the immediate and long-term societal costs [2,3,5,6]. Effective antenatal treat-
ments that can reduce the morbidities of preterm birth are clearly needed. A single course of
antenatal corticosteroids remains the ‘gold standard’ antenatal intervention to reduce the risk
of fetal and neonatal mortality related to preterm birth, but residual morbidity remains a prob-
lem [7].
Use of repeat prenatal corticosteroids for women who remain at risk of preterm birth to
prevent neonatal morbidity was first suggested in the early 1970s [8]. The Cochrane systematic
review assessing the use of repeat prenatal corticosteroids for women at risk of preterm birth
to prevent neonatal disease shows their use results in a clinically important reduction in both
the risk of respiratory distress syndrome (risk ratio 0.83, 95% confidence intervals [CIs] 0.75 to
0.91; eight trials; 3,206 infants; number needed to treat [NNT] 17, 95% CI 11 to 32) and of seri-
ous infant outcome (risk ratio 0.84, 95% CI 0.75 to 0.94; seven trials; 5,094 infants; NNT 30,
95% CI 19 to 79) [9]. These neonatal benefits support the use of repeat dose(s) of prenatal cor-
ticosteroids for women who have received an initial course of prenatal corticosteroids 7 or
more days previously and who remain at risk of preterm birth. However, the aggregate review
is unable to provide important details needed by guideline developers [10], clinicians, and
pregnant women and their families, notably, whether repeat prenatal corticosteroids are more
effective in some women by reason of their risk of preterm birth; what is the best gestational
age for administration for maximal benefit; and what dose, number of repeat doses, and timing
prior to birth are optimal.
To address these questions, the Prenatal Repeat Corticosteroid International IPD-MA
Study: assessing the effects using the best level of Evidence (PRECISE) Group was formed to
undertake an individual participant data (IPD) meta-analysis (MA) of the data from eligible
trials. This approach has the advantages of allowing for exploration of interactions between
Repeat prenatal corticosteroids prior to preterm birth
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treatment and characteristics at a participant level and enables examination of differential
treatment effects between subgroups [11,12,13].
Materials and methods
Results are reported using the Preferred Items for Reporting for Systematic Review and Meta-
analysis of Individual Participant Data (PRISMA-IPD Statement) checklist [14] (S1 Text). The
IPD-MA followed the published protocol [15] (S2 Text). The Child Youth and Women’s
Health Service Research Ethics Committee, South Australia, Australia, approved the study
(REC2334/12/13). The included trials had received country- and site-specific ethical review,
with individual participants providing written, informed consent.
Specific objectives
The objectives of the PRECISE IPD-MA were to assess, using IPD methods and MAs, the
effects on important clinical outcomes of repeat prenatal corticosteroid treatment given to
women at risk of preterm birth to benefit their infants, both short-term and long-term, and
whether the treatment effects differed by the following prespecified participant and treatment
characteristics [15]: the reason the women were at risk of preterm birth (e.g., antepartum
haemorrhage, preterm prelabour rupture of the membranes, preterm labour, hypertensive dis-
ease of pregnancy); the gestational age when the repeat prenatal corticosteroids were given;
and the dose, number of repeat doses, and timing prior to birth that treatment was given.
Eligibility criteria
Trials were eligible if they randomised women considered at risk of preterm birth (<37 weeks’
gestation), who had already received a single course of prenatal corticosteroids seven or more
days previously, to either corticosteroids—administered to the women intravenously, intra-
muscularly, or orally—or placebo/no placebo, and if they reported data on one or more of the
prespecified outcomes. Quasirandom study designs were not eligible.
Identifying studies: Information sources and search strategy
The search strategy developed by Cochrane Pregnancy and Childbirth was used [16]. This
identified trials from monthly searching of the Cochrane Central Register of Controlled Trials
(CENTRAL), weekly searches of MEDLINE, monthly searches of CINAHL (EBSCO), hand
searches of 30 journals and the proceedings of major conferences, and weekly current aware-
ness alerts for a further 44 journals plus monthly BioMed Central email alerts.
Search terms used were [repeat or multiple] and [antenatal or prenatal] and [corticosteroid�
or steroid� or glucocorticoid� or betamethason� or dexamethason� or hydrocortison�]. Date
of last search was 20 January 2015. The WHO/CTRP portal was accessed to identify any
recently completed or ongoing trials. There was no language restriction on searches. Trialists
within the PRECISE Group were asked if they knew of any unpublished or other trials.
Study selection processes
Eligibility of identified trials was assessed independently and unblinded by two members of
the PRECISE Project Team (PFM and TKM). Any differences regarding eligibility were
resolved by discussion.
Repeat prenatal corticosteroids prior to preterm birth
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Data collection processes and data items
The Chairperson of the PRECISE Project Team (CAC) contacted the investigators of all eligi-
ble studies to invite them to join the PRECISE Trialist Group and to include IPD data from
their trial in the IPD-MA. Prespecified variables were developed and defined by the PRECISE
Trialist Group. Investigators were asked if these variables were available or could be derived
for their study, and a coding system was developed.
Deidentified data were collected on all randomised women. These included baseline data
for descriptive purposes and analyses (reason at risk of preterm birth, gestational age at trial
entry, plurality of the pregnancy, expected date of birth) and details of the intervention
planned and given (date of randomisation, allocated intervention, type and dose of antenatal
corticosteroids given, mode of administration, number and frequency of repeat courses given)
together with the infant, childhood, and maternal outcomes to allow the planned analyses.
The data from the individual trials were recoded as needed and stored in a secure database
only accessible by the PRECISE Data Management Group. The individual trialists were asked
to verify their coded data prior to analyses. Data were checked for internal consistency,
extreme or missing values, errors, and consistency with published reports. Randomisation
methods and intervention details were cross-checked against trial protocols, clinical record
forms, and published reports for all trials. The PRECISE biostatistician (MV), project coordi-
nator (TKM), and data manager (SZ) liaised with the trialists to check any inconsistencies and
missing data. The final IPD dataset prepared from each trial was sent to the trialist for verifica-
tion before being included in the full PRECISE dataset. Data items collected are published else-
where [15] (S2 Text).
Risk of bias assessment in individual studies
Risk of bias for each study was assessed using the Cochrane Collaboration risk of bias tool [17]
by two members of the PRECISE Project Team (PFM and TKM) independently, with differ-
ences resolved by discussion. Each study was judged to have high, low, or unclear risk of bias
for random sequence generation (checking for possible selection bias), allocation concealment
(checking for possible selection bias), blinding of participants and personnel (checking for
possible performance bias), blinding of outcome assessment (checking for possible detection
bias), incomplete outcome data (possible attrition bias due to the amount, nature, and han-
dling of incomplete outcome data), selective reporting (checking for possible reporting bias),
and other bias (checking for bias due to problems not already covered). The magnitude and
direction of the bias and whether it was considered likely to affect the findings were assessed. If
any aspect was unclear, additional information was sought from the trialists.
Specification of outcomes and effect measures
The primary prespecified outcomes for the infant were serious outcome (defined by the PRE-
CISE Group as any of death [fetus, neonatal, infant, or child], severe respiratory disease as
defined by the trialists, grade 3 or 4 intraventricular haemorrhage, chronic lung disease [oxy-
gen dependent at 36 weeks postmenstrual age], definite necrotising enterocolitis, stage 3 or
worse retinopathy of prematurity in the better eye, or cystic periventricular leucomalacia); use
of respiratory support (defined as mechanical ventilation or continuous positive airways pres-
sure, ECMO, oscillatory ventilation, or any other form of assisted ventilation); and birth
weight z-scores.
The primary prespecified outcome for the child was death or any neurosensory disability at
childhood follow-up (defined as developmental delay or intellectual impairment [developmen-
tal quotient or intelligence quotient more than one standard deviation below the mean],
Repeat prenatal corticosteroids prior to preterm birth
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cerebral palsy [abnormality of tone with motor dysfunction], blindness ([corrected visual acu-
ity worse than 6/60 in the better eye], or deafness [hearing loss requiring amplification or
worse]).
The primary prespecified outcome for the woman was maternal sepsis (defined as chor-
ioamnionitis during labour, pyrexia after trial entry requiring the use of antibiotics, puerperal
sepsis, or intrapartum fever requiring the use of antibiotics or postnatal pyrexia).
Secondary outcomes were prespecified in the PRECISE IPD-MA protocol [15] (S2 Text).
Synthesis methods and additional analyses
The statistical analysis plan was prepared by the PRECISE Data Management Group and
agreed by the PRECISE Trialist Group. One-step IPD-MA analyses were conducted on the
checked IPD from all the trials. All randomised participants with outcome data available were
included in the analyses, performed on an intention-to-treat basis by treatment allocation at
randomisation.
Binary outcomes were analysed using log binomial regression models with results presented
as RRs with 95% CIs and associated two-sided p values. Continuous outcomes were analysed
using linear regression models, and results were presented as differences in means with 95%
CI and two-sided p values. Correlations between outcomes due to multiple births were taken
into account using generalised estimating equations (GEEs) for infant and child outcomes.
Differences in treatment effect between prespecified subgroups were assessed by testing a
treatment-by-subgroup interaction term within the model. A treatment-by-trial interaction
term was included in the model to assess heterogeneity of treatment effect across trials. When
excessive statistical heterogeneity in treatment effect or inconsistency across trials was
detected, then the rationale for combining trials was questioned and the source of heterogene-
ity explored.
For growth outcomes, z-scores were calculated at birth, hospital discharge, and follow-up
based on WHO Child Growth Standards and British 1990 reference data, reanalysed 2009
[18,19]. For composite outcomes, some trials did not collect all variables used to define the
composite. Analysis of composite outcomes included all trials that collected at least one vari-
able used to define the composite. Participants were classified as having the outcome if they
experienced any of the events contributing to the composite for which data were available and
classified as not having the outcome otherwise. Statistical significance was assessed at the
p< 0.05 level. NNT was calculated as the inverse of the absolute risk reduction (ARR):
NNT = 1/ARR, where ARR = Control Event Rate minus Experimental Event Rate.
Analyses presented do not correspond to published estimates from individual trials in every
case because trialists may have defined outcomes differently or prespecified different criteria
for inclusion or exclusion of data from their analysis. Discrepancies between published esti-
mates and PRECISE estimates do not imply that one or the other is incorrect.
Results
Study characteristics
Eleven randomised trials were identified from the search, and each provided data for the
IPD-MA [20–34], with a total of 4,857 women and 5,915 infants contributing data to the analy-
ses (Fig 1).
Five trials were from the US [23,24,26,27,33]; two from Canada [20,28]; and one each from
Australia and New Zealand [21], Finland [30], India [25], and the UK [31]. Details of the stud-
ies are described in Table 1.
Repeat prenatal corticosteroids prior to preterm birth
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Fig 1. PRECISE PRISMA-IPD flow diagram. IPD, individual participant data; MA, meta-analysis; PRECISE,
Prenatal Repeat Corticosteroid International IPD-MA Study: assessing the effects using the best level of Evidence;
PRISMA, Preferred Items for Reporting for Systematic Review and Meta-analysis.
https://doi.org/10.1371/journal.pmed.1002771.g001
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Table 1. Included trials and their characteristics.
Trial Participants included in IPD Interventions Comparator Outcomes
Aghajafari 2002,
Canada [20]
12 women (16 fetuses) 24–30 weeks’
gestation, at continued increased risk
of PTB 7 or more days following a
single course of ACS
2× 12 mg betamethasone (Celestone
Soluspan with 6 mg betamethasone
phosphate and 6 mg of betamethasone
acetate) 24 hours apart repeated
weekly until 33 weeks or birth, if still
at risk of PTB
saline placebo, two
courses, 24 hours
apart
Primary: Perinatal or neonatal mortality
or neonatal morbidity (including severe
RDS, IVH [grade 3 or 4], PVL, BPD, or
NEC).
Secondary neonatal: Weight, length, and
head circumference at birth, neonatal
infection, ROP, stay in NICU, use of
ventilation with intubation, and PDA
needing pharmacological treatment or
surgery.
Secondary maternal: Chorioamnionitis
and maternal infection after delivery.
Crowther 2006,
Australia and
New Zealand
[21,22]
982 women (1,147 fetuses) at <32
weeks’ gestation who had received
initial treatment with corticosteroid
�7 days previously
1× 11.4 mg betamethasone (Celestone
Chronodose with 7.8 mg
betamethasone sodium phosphate and
6 mg betamethasone acetate); repeated
weekly only if still at risk of PTB until
<32 weeks
saline placebo Primary: Frequency and severity of RDS;
severity of any respiratory disease present;
need for and duration of oxygen therapy;
need for and duration of mechanical
ventilation via an endotracheal tube
(including high frequency ventilation);
and weight, length, and head
circumference at birth and at discharge
from hospital.
Secondary: Clinical chorioamnionitis
requiring intrapartum antibiotics,
maternal postpartum pyrexia�38.0 ˚C,
any side effects of the injection for the
mother, and other measures of neonatal
morbidity for the infant.
Garite 2009,
USA [23]
437 women (577 fetuses) at 25 to <33
weeks’ gestation who had completed
a single course of corticosteroids
before 30 weeks, and at least 14 days
before inclusion, and were judged to
have a recurring threat of PTB in the
coming week
2× 12 mg betamethasone (as 6 mg
betamethasone sodium phosphate and
6 mg betamethasone acetate), 24 hours
apart or 4× 6 mg dexamethasone, 12
hours apart repeated once if birth
expected in�7 days
saline placebo Primary: Composite neonatal morbidity—
RDS, BPD, severe IVH, PVL, proven sepsis,
NEC, or perinatal death.
Secondary: GA at delivery, birth weight,
IUGR/SGA, head circumference,
ventilator days, days requiring
supplemental oxygen, need for surfactant
therapy, hospital days, pneumothorax,
maternal infectious morbidity
(chorioamnionitis and postpartum
endometritis).
Guinn 2001,
USA [24]
502 women (496 fetuses) 24 to <33
weeks’ gestation who had not
delivered 1 week after receipt of a
single course
2× 12 mg betamethasone, 24 hours
apart repeated weekly until 34 weeks
saline placebo Primary: Composite neonatal morbidity
(including severe RDS, BPD, severe IVH,
PVL, proven sepsis, NEC, perinatal death).
For the IPD-MA, some diagnostic criteria
differ from original publication [24], and
data analyses included all the infants.
Mazumder 2008,
India [25]
76 women (76 fetuses) 25–33 weeks
gestation who had not delivered
within 7 days of first betamethasone
course
2× 12 mg betamethasone (as
betamethasone sodium phosphate), 24
hours apart, repeated weekly until 34
weeks’ gestation
no further treatment Primary: Severe RDS.
Secondary: Short-term neonatal morbidity
(severe RDS, IVH, NEC, PDA, BPD,
sepsis, ROP, deaths within 28 days),
intrauterine growth (birth head
circumference, length, and weight),
medium-term neurodevelopmental
outcomes, medium-term postnatal growth
(head circumference, weight, and
recumbent length at 6 months).
(Continued)
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Table 1. (Continued)
Trial Participants included in IPD Interventions Comparator Outcomes
McEvoy 2002,
USA [26]
37 women (37 fetuses) at 25–33
weeks’ gestation who remained
undelivered 1 week after their first
course of ACS
2× 12mg betamethasone (Celestone
Soluspan with 6 mg betamethasone
phosphate and 6 mg of betamethasone
acetate), 24 hours apart repeated
weekly until 34 weeks’ gestation or
until birth
weekly saline placebo
until 34 weeks’
gestation or until
birth
Primary: Measurement of FRC.
Secondary: Measurement of respiratory
compliance and other important clinical
respiratory outcomes including need for
surfactant, days on oxygen, and
mechanical ventilation.
McEvoy 2010,
USA [27]
85 women (113 fetuses) at 26 to <34
weeks’ gestation who had been given
an initial course of ACS and
remained undelivered 14 days after
therapy but still at high risk for
preterm delivery
2× 12 mg betamethasone (Celestone
Soluspan with 6 mg betamethasone
phosphate and 6 mg of betamethasone
acetate), 24 hours apart with a single
repeat course of ACS
placebo Primary: Measurement of passive
respiratory mechanics and FRC within 72
hours of age, weekly for first month,
monthly until discharge.
Secondary: Clinical outcomes at
discharge, follow-up pulmonary function
tests at 6 months, 1 year, and 2 years
corrected age; clinical respiratory
outcomes, growth measurements, and
neurodevelopmental outcome will be
followed through 2 years of age.
Murphy 2008,
Canada [28,29]
1,858 women (2,318 fetuses) at 25–32
weeks gestation who remained
undelivered 14–21 days after an
initial course of ACS and continued
to be at high risk of PTB
2× 12 mg betamethasone (Celestone
with 6 mg betamethasone sodium
phosphate and 6 mg betamethasone
acetate), 24 hours apart, repeated
fortnightly until 33 weeks’ gestation
Placebo group—
dilute concentration
of aluminium
monostearate
Primary: Perinatal or neonatal mortality
or neonatal morbidity (including severe
RDS, IVH (grade 3 or 4), PVL, BPD, or
NEC).
Secondary neonatal: Weight, length, and
head circumference at birth, neonatal
infection, ROP, stay in NICU, use of
ventilation with intubation, and PDA
needing pharmacological treatment or
surgery.
Secondary maternal: Chorioamnionitis
and maternal infection after delivery.
Peltoniemi 2007,
Finland [30]
249 women (326 fetuses) with
imminent delivery before 34 weeks’
gestation who remained undelivered
for >7 days after a single course of
betamethasone
1× 12 mg betamethasone (Celestone
Chronodose with betamethasone
phosphate and betamethasone acetate)
repeated once if birth expected in <48
hours
saline placebo Primary: Survival without RDS or severe
IVH (grade 3 or 4).
Secondary: Cystic PVL, NEC of grade�2,
BPD, PDA.
TEAMS, UK
[31,32]
156 women (182 fetuses)<32 weeks
gestation and had received one
course of ACS
2× 12 mg betamethasone, 12 or 24
hours apart, usually repeated every 7
days but could be 10–14 days
depending on unit’s protocol
placebo Primary: Death in first year after birth,
developmental quotient <85 at 2 years.
Secondary short-term: Intrauterine death
after 24 weeks gestation, neonatal death,
postneonatal death, RDS, pneumothorax
or other pulmonary air leak, intracerebral
abnormality diagnosed on ultrasound scan
before discharge, NEC, CLD, evidence of
infection on blood culture before and after
first 48 hours after birth, birth weight,
head circumference at birth,
chorioamnionitis, maternal postpartum
infection.
Secondary long-term: Growth at age 2
years (corrected), respiratory symptoms at
age 2 years (corrected), sub-scale scores
for the Vineland Adaptive Behaviour
Scales at age 2 years (corrected), blood
pressure at age 2 years (corrected),
readmission to hospital.
(Continued)
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Individual study protocols varied in relation to the amount and number of doses used in a
course of repeat treatment, the interval between courses, and the latest gestation that repeat
treatment courses could be given. In most trials, a course of treatment was two doses,
usually given 24 hours apart, although for two trials, a course of treatment was a single
dose [21,30]. Seven of the trials allowed a course of repeat treatment at 7-day intervals
[20,21,24,25,26,31,33], and one trial at 14-day intervals [28]. Most of these trials repeated the
course of treatment until 33–34 weeks gestation [24,25,26,28,31,33]. In two trials [20,21], a
Table 1. (Continued)
Trial Participants included in IPD Interventions Comparator Outcomes
Wapner 2006,
USA [33,34]
495 women (594 fetuses) 23 to <32
weeks’ gestation and at risk for
spontaneous PTB for any reason or
placenta praevia or chronic abruption
and received a full course of
corticosteroids within the previous 7
days
2× 12 mg betamethasone (as 6 mg
betamethasone sodium phosphate and
6 mg betamethasone acetate), 24 hours
apart or 4× 6 mg dexamethasone 12
hours apart, repeated weekly until 34
weeks gestation
placebo. Primary: Stillbirth or neonatal mortality,
severe RDS, grade 3–4 IVH, PVL, CLD.
Secondary maternal: Chorioamnionitis,
postpartum endometritis, premature
PROM, time from randomisation to
PROM, time from randomisation to
delivery, abnormal 1-hour glucose
tolerance test, gestational diabetes,
pulmonary oedema, infectious morbidity
(highest temperature within 24 hours of
birth, sepsis, need for antibiotics), days
hospitalised postpartum, IL-1, IL-2, IL-4,
IL-6, IL-10, IFN-γ, cortisol,
rehospitalisations after delivery until 6
weeks postpartum.
Secondary placental: Weight, histologic
chorioamnionitis, fibrosis, vascular
changes.
Secondary neonatal: Birth weight, head
circumference, upper arm circumference,
neonatal infectious morbidity (sepsis,
suspected sepsis, pneumonia), neonatal
noninfectious morbidity (RDS, NEC,
gastrointestinal perforation, seizures/
encephalopathy, PDA, hypertension,
ROP), days in NICU, GA at delivery, IL-1,
IL-2, IL-4, IL-6, IL-10, IFN-γ, cortisol,
TSH, free T4 and cholesterol levels, ABR
interpeak interval (I–V).
Secondary infant: Frequency of
hospitalisations since birth, weight, and
head circumference at the 24-month
exam, hypertension at the 24-month exam,
cerebral palsy (subclassified as mild,
moderate, or severe, diagnosed at the
24-month exam), neonatal or infant death,
Motor and Mental Scales score from the
Bayley Scales of Infant Development II at
24 months’ corrected age, Intelligence
Scale score from the McCarthy Scales of
Children Abilities at 36 months’ corrected
age.
Abbreviations: ABR, auditory brainstem response; ACS, antenatal corticosteroids; BPD, bronchopulmonary dysplasia; CLD, chronic lung disease; FRC, functional
residual capacity; GA, gestational age; IFN-γ, interferon gamma; IL, interleukin; IPD, individual participant data; IUGR, intrauterine growth restriction; IVH,
intraventricular haemorrhage; MA, meta-analysis; NEC, necrotising enterocolitis; NICU, neonatal intensive care unit; PDA, patent ductus arteriosus; PROM, prelabour
rupture of the membranes; PTB, preterm birth; PVL, periventricular leucomalacia; RDS, respiratory distress syndrome; ROP, retinopathy of prematurity; SGA, small for
gestational age; TEAMS, Trial of the Effects of Antenatal Multiple courses of Steroids versus a single course; TSH, thyroid stimulating hormone.
https://doi.org/10.1371/journal.pmed.1002771.t001
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course of repeat treatment was only given if the risk of preterm birth remained: until 32 weeks
for one trial [21] and 33 weeks for the other [20]. Three trials specifically targeted women for
‘rescue therapy’ (repeat doses only given when preterm birth was again considered imminent)
[23,27,30]. The characteristics of the populations, including the main reason at risk of preterm
birth at trial entry, for the included trials are given in Table 2. Not all trials were able to provide
data for all the endpoints analysed.
Risk of bias across studies
Overall the risk of bias was low across the included studies, with some variation between the
trials (Table 3).
Primary outcomes for the infant
Serious outcome. There was no statistically significant effect of repeat prenatal corticoste-
roids compared with no repeat treatment on the risk of serious outcome for the infant (RR
0.92, 95% CI 0.82 to 1.04), with no significant heterogeneity (p = 0.33) (Fig 2).
Use of respiratory support. There was a statistically significant reduction in the use
of respiratory support in infants exposed to repeat prenatal corticosteroids compared with
infants not exposed (RR 0.91, 95% CI 0.85 to 0.97), with no significant heterogeneity (p = 0.64)
Table 2. Characteristics of mothers and main reasons for PTB at trial entry for the included trials.
Characteristic Aghajafari
2002
Crowther
2006
Garite
2009
Guinn
2001
Mazumder
2008
McEvoy
2002
McEvoy
2010
Murphy
2008
Peltoniemi
2007
TEAMS
[31]
Wapner
2006
Maternal age (years) 32.4 (5.7) 30.4 (6) 29 (6.2) 27.5 (7) 26.6 (4.2) 24.8 (5.9) 27.7 (7) 29.1 (6.2) 30.7 (5.8) 28.6 (6) 25.9 (5.9)
GA (weeks) 27.4 (1.9) 28.3 (2.2) 29.6
(2.1)
29 (2.7) 30.2 (1.6) 29.9 (2.4) 30.1 (2) 29.3 (2) 30.4 (2.6) 28.8 (1.9) 28.1 (2.4)
Previous pregnancies 7 (58) 671 (68) 257 (59) 338 (67) 48 (63) 15 (41) 69 (81) 1,338 (72) 435 (88)
Multiple pregnancy 4 (33) 155 (16) 141 (32) 73 (15) 7 (9)† 0 (0) 28 (33) 390 (21) 70 (28) 20 (12) 101 (20)
Previous PTB (<37
weeks gestation)
2 (16.7) 164 (16.7) 142
(28.3)
21 (13.3) 638 (34.3) 11 (4.4) 244 (45.9)
Main reason for risk of PTB
Preterm labour NA 257 (26) NA 270 (54) 15 (20) 31 (84) 67 (79) 1,554 (84) 83 (33) 46 (28) 205 (41)
Placental abruption NA 44 (4) NA 35 (7) 0 (0) 1 (3) 8 (9) NA 55 (22) NA 25 (5)
Placenta praevia NA 137 (14) NA 38 (8) 15 (20) 2 (5) 8 (9) NA NA 3 (2) 30 (6)
Ruptured
membranes
5 (42) 334 (34) 0 (0) 120 (24) 12 (16) 19 (51) 17 (20) 291 (16) 95 (38) 30 (19) 0 (0)
Antepartum
haemorrhage
2 (17) 282 (29) NA 44 (9) 0 (0) 3 (8) 4 (5) 260 (14) NA 2 (1) 0 (0)
Pre-eclampsia NA 97 (10) NA 54 (11) 14 (18) 4 (11) 9 (11) 96 (5) 55 (22) 14 (9) 0 (0)
Fetal growth
restriction
0 (0) 51 (5) NA 35 (7) 3 (4) 0 (0) 7 (8) 159 (9) 64 (25) 5 (3) 0 (0)
Suspected fetal
jeopardy
0 (0) NA NA 33 (7) 10 (13) 0 (0) 4 (5) 218 (12) 155 (62) 5 (3) 0 (0)
Cervical
incompetence
4 (33) 82 (8) NA NA 0 (0) 5 (14) 25 (29) 909 (49) NA 1 (1) 71 (14)
Maternal disease 3 (25) NA NA 152 (30) 6 (8) 2 (5) 15 (18) 391 (21) NA 4 (2) 0 (0)
Multiple pregnancy 4 (33) 43 (4) 141 (32) 73 (15) 2 (3) 0 (0) 28 (33) 370 (20) 70 (28) 16 (10) 101 (20)
Figures are numbers (percentages) or mean and standard deviation.
†Only data from firstborn available for analysis.
Abbreviations: GA, gestational age; NA, Not Available; PTB, preterm birth; TEAMS, Trial of the Effects of Antenatal Multiple courses of Steroids versus a single course.
https://doi.org/10.1371/journal.pmed.1002771.t002
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(Fig 3). The NNT to benefit was 21 women/fetuses (95% CI 14 to 41) to prevent one infant
from needing respiratory support.
Birth weight. There was a significantly lower birth weight z-score in infants exposed to
repeat prenatal corticosteroids compared with unexposed infants (mean difference –0.12, 95%
CI –0.18 to –0.06) (Fig 4), with no heterogeneity among the trials (p = 0.80).
Primary outcomes for the child. There was no statistically significant effect of treatment
with repeat prenatal corticosteroids on the risk of death or neurosensory disability for the
child (Fig 5).
Primary outcomes for the woman. For the primary maternal outcomes of maternal sep-
sis, no statistically significant effect was seen with repeat corticosteroids using the data avail-
able for the IPD (Fig 6).
Secondary outcomes
For the infant. No statistically significant differences were seen for many of the second-
ary infant outcomes (S1 Table). Fewer infants in the repeat corticosteroid group compared
with infants in the no-repeat group required resuscitation at birth, ongoing respiratory sup-
port, surfactant treatment, or oxygen supplementation, they were less likely to have respira-
tory distress syndrome, and any respiratory disease was less severe (S1 Table). However,
birth weight, length, and head circumference measurements were all lower in the repeat
corticosteroid group, and there were proportionately more small for gestational age infants
compared with the no-repeat group (S1 Table). Systolic, diastolic, and mean arterial blood
pressures were significantly lower in infants exposed to repeat corticosteroids compared with
nonexposed infants, although fewer than 10% of infants had data reported for these outcomes
(S1 Table).
For the children. For the children, no statistically significant differences were seen for
the outcomes of death, neurosensory impairments, any neurosensory disability, major
Table 3. Risk of bias within studies.
Trial Randomisation1 Concealment2 Performance3 Detection4 Attrition5 Reporting6
Aghajafari 2002 Low Low Low Unclear Low Low
Crowther 2006 Low Low Low Low Low Low
Garite 2009 Low Low Low Low Low Low
Guinn 2001 Low Low Low Low Low Low
Mazumder 2008 Low Low High Unclear Unclear Unclear
McEvoy 2002 Low Low Low Low Low Low
McEvoy 2010 Low Low Low Low Low Low
Murphy 2008 Low Low Low Low Low Low
Peltoniemi 2007 Low Low Low Low Unclear Low
TEAMS [31] 1999 Low Low Low Low Unclear Low
Wapner 2006 Low Low Low Low Unclear Low
1Random sequence generation.
2Allocation concealment.
3Blinding of participants and personnel.
4Blinding of outcome assessment.
5Incomplete outcome data.
6Selective reporting.
Abbreviations: TEAMS, Trial of the Effects of Antenatal Multiple courses of Steroids versus a single course.
https://doi.org/10.1371/journal.pmed.1002771.t003
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neurosensory disability, child behaviour, or respiratory disease at follow-up; however, weight
z-scores and systolic blood pressure were lower (S2 Table).
For the woman. No statistically significant differences were seen in any of the secondary
outcomes for the woman, including the individual components of the primary outcome of
maternal sepsis, preterm prelabour rupture of the membranes, hypertension, mode of birth,
postpartum haemorrhage, breast feeding at discharge, postnatal depression, or adverse effects
of corticosteroid therapy (including gastrointestinal upset, glucose intolerance, insomnia, pain
at the injection site, bruising at the injection site, infection at injection site, weight gain, Cush-
ingoid appearance). For the composite outcome of adverse effects of corticosteroid therapy,
the p-value for heterogeneity was <0.0001, indicating differences between the studies not
accounted for by random variation, such as differences in the placebo used (S3 Table). There
were no maternal deaths reported.
Subgroup analyses
When sufficient data existed, subgroup comparisons were conducted using the five primary
outcomes for the infant, child, and mother, as well as the individual components of each com-
posite outcome. Not all planned subgroup analyses were possible because of unavailability of
data. When subgroup analyses were possible, not all trials had data to contribute.
Fig 2. Primary outcome for the infant: Serious outcome. Serious outcome is defined as any death (fetal, neonatal, infant, or child),
severe respiratory disease as defined by the trialists, grade 3 or 4 IVH, CLD (oxygen dependent at 36 weeks postmenstrual age), definite
NEC, stage 3 or worse ROP in the better eye, or cystic PVL. Figures are numbers (percentages) with RR and 95% CI as treatment effect. p-
value for heterogeneity = 0.33. CI, confidence interval; CLD, chronic lung disease; IVH, intraventricular haemorrhage; NEC, necrotising
enterocolitis; PVL, periventricular leucomalacia; ROP, retinopathy of prematurity; RR, relative risk; TEAMS, Trial of the Effects of
Antenatal Multiple courses of Steroids versus a single course.
https://doi.org/10.1371/journal.pmed.1002771.g002
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The prespecified participant level characteristics that were analysed were the reason the
woman was considered to be at risk of preterm birth, the number of fetuses in utero, gesta-
tional age when first trial treatment course was given (trial entry), the time prior to birth that
the last dose of trial treatment course was given, the number of courses received, the interval
between courses, and the total dose received.
Reason the woman was considered to be at risk of preterm birth. There were few clear
differences in treatment effects among subgroups of reasons the women were considered at
risk of preterm birth. Reductions in birth weight, head circumference, and length due to
receiving repeat corticosteroids were greater when the reason for being at risk of preterm birth
was preterm labour than when it was not (S4 Table). For those whose reason for preterm birth
was fetal growth restriction, reduction in birth weight due to repeat corticosteroid treatment
was less likely than when the reason for preterm birth was not fetal growth restriction (S4
Table). Developmental delay/intellectual impairment was more likely when the reason for pre-
term birth was maternal disease than when it was not (S4 Table).
Number of fetuses in utero (singleton versus multiple birth). There were no significant
differences in treatment effects among the subgroups by the number of fetuses in utero (S5
Table).
Gestational age when first repeat treatment course was given. Reductions in birth
weight, head circumference, and length were significantly greater for infants whose mothers
had received corticosteroids at an earlier gestational age. Women starting treatment at earlier
gestations were a subgroup who also received higher total exposure overall (S6 Table).
Fig 3. Primary outcome for the infant: Use of respiratory support. Figures are numbers (percentages) with RR and 95% CI as treatment
effect. p-value for heterogeneity = 0.64. CI, confidence interval; RR, relative risk; TEAMS, Trial of the Effects of Antenatal Multiple courses
of Steroids versus a single course.
https://doi.org/10.1371/journal.pmed.1002771.g003
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Time prior to birth last dose of trial treatment course was given. There were no signifi-
cant differences in treatment effects for any of the major outcomes according to categories of
time prior to last dose of treatment until birth (S7 Table).
Number of courses of repeat prenatal corticosteroids received. The number of courses
of repeat prenatal corticosteroids received varied by trial due to the different treatment proto-
cols. The number of courses also varied by participant characteristics such as the gestational
age at which study treatment commenced, with women commencing at an earlier gestational
age having more time to receive more courses of treatment provided birth did not occur. Half
of the children in the analyses were exposed to only one course of treatment. Only 3% of chil-
dren were exposed to six or more courses of treatment. CIs for this subgroup were therefore
wide because of the smaller number of participants in the analysis. Because the number of
courses received was a postrandomisation measurement, these analyses were considered
exploratory, although still clinically important, comparisons. For the primary outcomes of seri-
ous outcome and use of respiratory support for the infant, treatment effects differed according
to the number of courses of repeat treatments received. Benefits of repeat corticosteroid were
observed for infants who were exposed to between 2 to 5 courses of repeat corticosteroids
compared with infants exposed to only a single repeat course or 6 or more repeat courses.
There were greater reductions in birth weight and length z-scores for infants exposed to 4 or
more repeat courses and in head circumference for infants exposed to two or more repeat
courses (S8 Table).
Minimum actual interval between repeat treatment courses. The minimum interval
between repeat treatment courses varied by trial because of the different treatment protocols
Fig 4. Primary outcome for the infant: Birth weight (z-scores). Figures are mean and standard deviation, with adjusted mean difference as treatment effect and
95% CI. p-value for heterogeneity = 0.80. CI, confidence interval; TEAMS, Trial of the Effects of Antenatal Multiple courses of Steroids versus a single course.
https://doi.org/10.1371/journal.pmed.1002771.g004
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and different participants. Intervals between repeat courses of 1–7 days and 8 or more days
showed a reduction in serious outcome and the use of respiratory support for infants exposed
to repeat courses compared with a single repeat course. For the other outcomes, apart from
death at any time, no obvious differences were seen between groups for different minimum
interval between repeat treatment courses (S9 Table).
Actual total dose of trial treatment received. The dose of trial treatment received varied
by trial because of the different trial protocols and also because of the number of courses of
treatment actually received. Differences in treatment effects were seen for serious outcome for
the infant, use of respiratory support, death at any time, and head circumference depending on
the total dose received. Benefits of repeat corticosteroids were seen for serious outcome for the
infant and for use of respiratory support with larger doses (>24 mg) and for death at any time
with total doses between >24 mg to 48 mg of repeat corticosteroid compared with total doses
received of�24 mg (S10 Table). Head circumference z-scores at birth were reduced if total
doses of corticosteroid received was>24 mg compared with total doses of�24 mg (S10 Table).
Discussion
Summary of evidence
The major findings from the PRECISE IPD-MA are that for women at risk of preterm birth,
use of repeat prenatal corticosteroids following an initial course 7 or more days previously
Fig 5. Primary outcome for the child: Death or any neurosensory disability. Neurosensory disability at childhood follow-up defined as
developmental delay or intellectual impairment (developmental quotient or intelligence quotient more than one standard deviation
below the mean), cerebral palsy (abnormality of tone with motor dysfunction), blindness (corrected visual acuity worse than 6/60 in the
better eye), or deafness (hearing loss requiring amplification or worse). Figures are numbers (percentages) with RR and 95% CI. p-value
for heterogeneity 0.96. CI, confidence interval; RR, relative risk; TEAMS, Trial of the Effects of Antenatal Multiple courses of Steroids
versus a single course.
https://doi.org/10.1371/journal.pmed.1002771.g005
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does not reduce the risk of serious outcome for their infant but does reduce the risk of their
infant needing respiratory support after birth. The number of women who need to be treated
to prevent one infant needing respiratory support is 21 (95% CI 14 to 41). This benefit is asso-
ciated with their infant being less likely to have respiratory distress syndrome, having less
severe respiratory disease, and being less likely to require resuscitation at birth, surfactant
treatment, and oxygen supplementation. These respiratory benefits are not at the expense of
any short-term complications for the mother. However, z-scores for weight are significantly
lower in infants whose mothers receive repeat prenatal corticosteroids (mean difference 80 g),
as are z-scores for head circumference and length at birth and the proportion of infants born
small for gestational age. The clinical significance of the reduction in birth weight z-scores is
unclear. There appear to be no longer-term clinical benefits or harms of repeat prenatal corti-
costeroids in childhood, as assessed by neurosensory disabilities, respiratory outcomes, or
behaviour, and few differences in body size, although weight z-scores are lower by –0.11 SD
(95% CI –0.19 to –0.03). The clinical importance of this reduction in weight z-score at early
childhood follow-up, in the absence of clear evidence of effects on head size, length/height, or
neurosensory outcomes is unclear. There is also a small reduction in systolic blood pressure of
uncertain clinical importance. Ex-preterm survivors have higher blood pressure in late adoles-
cence or early adulthood than do term controls [35], which may predispose them to more car-
diovascular disease in adult life. Since blood pressure tracks through childhood into late
adolescence in preterm survivors [36], a small reduction in child blood pressure may be a
Fig 6. Primary outcomes for the women: Maternal sepsis. Maternal sepsis defined as one of the following: chorioamnionitis during
labour, pyrexia after trial entry requiring the use of antibiotics, puerperal sepsis, intrapartum fever requiring the use of antibiotics, or
postnatal pyrexia. Figures are numbers (percentages) with RR and 95% CI. p-value for heterogeneity 0.22. CI, confidence interval; RR,
relative risk; TEAMS, Trial of the Effects of Antenatal Multiple courses of Steroids versus a single course.
https://doi.org/10.1371/journal.pmed.1002771.g006
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long-term benefit of repeat doses of corticosteroids. Follow-up into adolescence and adult life
is needed to clarify this.
The results from this IPD-MA are consistent with the aggregate meta-analysis in the
Cochrane review assessing the use of repeat prenatal corticosteroids in women who remain at
risk of preterm birth after an initial course of corticosteroids [9]. The new information that
this IPD-MA has clarified is that no specific subgroup of infants benefitted more or less from
exposure to repeat prenatal corticosteroids, including plurality, the gestational ages when
repeat treatment was first given, or the time prior to birth the last repeat treatment was given.
In three subgroup analyses involving postrandomisation events (the minimum actual inter-
val between repeat treatment courses, the number of repeat prenatal corticosteroids courses
received, and the total dose of corticosteroids received), differences were seen between sub-
groups. The risk of a serious outcome for the infant and the need for respiratory support were
reduced when exposed to at least 2 repeat treatment courses and to total doses of more than 24
mg of repeat treatment. Death at any time was reduced with exposure to total doses of between
>24 mg to 48 mg.
The number of repeat prenatal corticosteroid treatment courses and the total dose of repeat
prenatal corticosteroids also affected body size z-scores at birth, with exposure to increasing
numbers of repeat treatment courses or larger total doses associated with greater reductions in
growth. There were greater reductions in birth weight for infants exposed to 4 or more repeat
courses. To provide clinical benefit with the least harm in women who remain at high risk of
preterm birth 7 or more days after an initial course of corticosteroids, it would seem prudent
to limit the use of any repeat corticosteroids to a total dose of between>24 mg to 48 mg and a
maximum of 3 repeat courses of treatment.
Strengths and limitations
IPD-MA is recognised as the gold standard for systematic reviews [11]. One of the strengths of
this IPD-MA is that all the trialists were willing to be part of the PRECISE Group collaborative
initiative and provide their data. All the trials used betamethasone—there are no IPD-MA data
for dexamethasone.
In this way, we were able to include IPD from all the known completed randomised trials of
repeat prenatal corticosteroid treatment given to women at risk of preterm birth to benefit
their infants. The IPD-MA findings provide the best available evidence for decision makers at
this time.
We have recently updated the search for trials (date of search 22 January 2019). No addi-
tional randomised trials of repeat prenatal corticosteroid treatment given 7 or more days after
an initial course of prenatal corticosteroids were identified. Two of the trials have reported
health outcomes in later childhood, one at 5 years [37] and the other 6–8 years of age [38].
Both trials found no differences between children exposed to repeat prenatal corticosteroids
and those not in the risk of death or neurodevelopmental disability or in body size measure-
ments [37,38].
Not all trials collected or were able to provide data for all of the prespecified subgroups.
This limited the power to be able to detect overall or subgroup differences because event
rates are low for some important maternal, infant, and childhood clinical outcomes. Neonatal
hypoglycaemia was not reported in any of the trials but has recently been linked with use of
antenatal corticosteroids in the late preterm period [39], so it should be assessed in any future
primary studies. Several of the planned subgroup analyses were for events that happened after
randomisation, including number of repeat treatments given, the timing prior to birth repeat
treatment was given, and the total dose received. Interpretation of these results should be
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cautious because postrandomisation events may be affected by the treatment given. Although
such events are more subject to bias, our purpose was to identify mothers and infants within
subgroups who would benefit most from treatment. This would enable use of repeat prenatal
corticosteroid treatment to be optimally targeted.
Conclusions
The PRECISE IPD-MA found that repeat prenatal corticosteroids given to women at ongoing
risk of preterm birth after an initial course reduces the likelihood of their infant needing respi-
ratory support after birth and leads to other respiratory benefits. Body size measurements at
birth are lower in infants whose mothers had received repeat prenatal corticosteroids, and the
reductions in weight z-scores and systolic blood pressure seen at childhood follow-up are of
uncertain clinical importance. No longer-term clinical benefits or harms are seen in childhood
for neurosensory disabilities, respiratory outcomes, or behaviour.
Prenatal corticosteroids are easy to administer, relatively inexpensive, and are effective at
reducing the need for respiratory support that preterm infants often require. Recommenda-
tions to use repeat prenatal corticosteroids when indicated are now included within the WHO
recommendations on interventions to improve preterm birth outcomes [40] and several
national clinical practice guidelines [10,41,42]. More widespread adoption could lead to signif-
icant global health and economic benefits [43].
It is reassuring that the respiratory benefit is seen among varying reasons for risk of preterm
birth, in singleton and multiple pregnancies, and across a range of preterm gestational ages
when repeat treatment courses are first given and times prior to birth the last repeat treatment
is given. Because the benefits of reduced serious outcome and need for respiratory support for
the infant are accompanied by a reduction in measures of body size at birth that are related to
the number of repeat treatment courses and total dose of repeat prenatal corticosteroid treat-
ment given, it would seem prudent to limit the use of repeat corticosteroids in women who
remain at high risk of preterm birth to a total dose of between >24 mg to 48 mg and a maxi-
mum of three repeat courses of treatment.
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